Home Cart Sign in  
Chemical Structure| 1020149-73-8 Chemical Structure| 1020149-73-8

Structure of SGI-1027
CAS No.: 1020149-73-8

Chemical Structure| 1020149-73-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SGI-1027 is a DNA methyltransferase (DNMT) inhibitor with IC50 values of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1, respectively, using poly(dI-dC) as a substrate.

Synonyms: DNA Methyltransferase Inhibitor II

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SGI-1027

CAS No. :1020149-73-8
Formula : C27H23N7O
M.W : 461.52
SMILES Code : O=C(NC1=CC=C(NC2=NC(N)=NC(C)=C2)C=C1)C3=CC=C(NC4=CC=NC5=CC=CC=C45)C=C3
Synonyms :
DNA Methyltransferase Inhibitor II
MDL No. :MFCD27937047
InChI Key :QSYLKMKIVWJAAK-UHFFFAOYSA-N
Pubchem ID :24858111

Safety of SGI-1027

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of SGI-1027

epigenetics

Isoform Comparison

Biological Activity

Target
  • DNA Methyltransferase

    DNMT3A, IC50:7.5 μM

    DNMT1, IC50:6 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 0-100 µM SGI-1027 inhibits the interaction between GST-MKK3 and VF-MYC Bioorg Med Chem. 2021 Sep 1;45:116324.
DNMT1 10 µM (IC50) 2 hours To study the mechanism of inhibition of DNMT1 by SGI-1027, results showed it as a DNA-competitive and AdoMet non-competitive inhibitor J Biol Chem. 2015 Mar 6;290(10):6293-302.
DNMT1 10 µM (IC50) 2 hours To study the mechanism of inhibition of DNMT1 by SGI-1027, results showed it as a DNA-competitive and AdoMet non-competitive inhibitor J Biol Chem. 2015 Mar 6;290(10):6293-302.
HEK293 cells 10 µM 20 minutes Evaluate the inhibitory effect of SGI-1027 and its derivatives on Rlig1-AMP, results showed that SGI-1027 and some of its derivatives effectively inhibited Rlig1-AMP activity Chem Sci. 2025 Jan 18;16(7):3313-3322.
HeLa cells 1 µM 24 hours To evaluate the effect of SGI-1027 in combination with AH057 on cell cycle in HeLa cells, results showed that the combined treatment increased the proportion of cells in G1 phase. Cell Death Dis. 2020 Sep 7;11(9):724.
HeLa cells 1 µM 24 hours To evaluate the effect of SGI-1027 in combination with AH057 on apoptosis in HeLa cells, results showed that the combined treatment significantly increased the percentage of apoptotic cells. Cell Death Dis. 2020 Sep 7;11(9):724.
Leukemia KG-1 cells 1-10 µM 24 hours To test the ability of the compounds to reactivate the luciferase reporter gene controlled by a methylated CMV promoter. Results showed that SGI-1027 induced a 16-fold luciferase expression at 5 μM, but at 10 μM, the signal decreased due to cytotoxicity. ChemMedChem. 2014 Mar;9(3):590-601.
MDA-MB-231 breast cancer cells 0.9 µM 48 hours To evaluate cell viability and proliferation, results showed that MC3353 significantly inhibited cell viability and proliferation Clin Epigenetics. 2019 May 6;11(1):68.
PC-3 prostate cancer cells 0.9 µM 48 hours To evaluate cell viability and proliferation, results showed that MC3353 significantly inhibited cell viability and proliferation Clin Epigenetics. 2019 May 6;11(1):68.
RAJI Burkitt’s lymphoma cells 0.4 µM 48 hours To evaluate cell viability and proliferation, results showed that MC3353 significantly inhibited cell viability and proliferation Clin Epigenetics. 2019 May 6;11(1):68.
U-937 acute myeloid leukemia cells 0.4 µM 48 hours To evaluate cell viability and proliferation, results showed that MC3353 significantly inhibited cell viability and proliferation Clin Epigenetics. 2019 May 6;11(1):68.
HCT116 colon cancer cells 0.5 µM 48 hours To evaluate antiproliferative activity, results showed that MC3353 significantly inhibited cell proliferation Clin Epigenetics. 2019 May 6;11(1):68.
HK-2 cells 3.916 µM 48 hours To evaluate the cytotoxicity of SGI-1027 on renal cancer cells and HK-2 cells, it was found that SGI-1027 inhibited the cell viability of all tested cell lines in a dose-dependent manner Adv Sci (Weinh). 2024 Oct;11(38):e2404693.
Caki-1 cells 2.965 µM 48 hours To evaluate the cytotoxicity of SGI-1027 on renal cancer cells and HK-2 cells, it was found that SGI-1027 inhibited the cell viability of all tested cell lines in a dose-dependent manner Adv Sci (Weinh). 2024 Oct;11(38):e2404693.
A-498 cells 1.702 µM 48 hours To evaluate the cytotoxicity of SGI-1027 on renal cancer cells and HK-2 cells, it was found that SGI-1027 inhibited the cell viability of all tested cell lines in a dose-dependent manner Adv Sci (Weinh). 2024 Oct;11(38):e2404693.
786-O cells 1.121 µM 48 hours To evaluate the cytotoxicity of SGI-1027 on renal cancer cells and HK-2 cells, it was found that SGI-1027 inhibited the cell viability of all tested cell lines in a dose-dependent manner Adv Sci (Weinh). 2024 Oct;11(38):e2404693.
Primary osteoblasts 10 µM 48 hours SGI-1027 alleviated the ferroptotic changes caused by FAC, but not by a GPX4 inactivator RSL3 Bone Res. 2024 Dec 2;12(1):68.
Osteoblasts 10 µM 48 hours SGI-1027 reversed titanium particle (TP)-induced GPX4 repression and ferroptotic changes, restoring GPX4 expression and reducing the lipid peroxidation marker 4-HNE. Research (Wash D C). 2024 Aug 19;7:0457.
SMB cells 50 nM (IC50) 5 days Evaluate the effect of SGI-1027 on PrPSc elimination, results showed that SGI-1027 effectively eliminated PrPSc Acta Pharm Sin B. 2019 Sep;9(5):952-959.
ScN2a cells 50 nM (IC50) 5 days Evaluate the effect of SGI-1027 on PrPSc elimination, results showed that SGI-1027 effectively eliminated PrPSc Acta Pharm Sin B. 2019 Sep;9(5):952-959.
KG-1 acute myeloid leukemia cells 1 µM 5 hours To evaluate CMV promoter-driven luciferase reporter system, results showed that MC3353 significantly enhanced luciferase expression Clin Epigenetics. 2019 May 6;11(1):68.
HK2 cells 10 µM 60 hours Evaluate the restorative effect of SGI-1027 on KLOTHO and NRF2 expression Aging Cell. 2022 Jan;21(1):e13526.
N2a cells 1 µM 96 hours Evaluate the effect of SGI-1027 on prion infection prevention, results showed that SGI-1027 effectively prevented prion infection Acta Pharm Sin B. 2019 Sep;9(5):952-959.
DNMT3Acat 0.8 µM (IC50) To study the inhibitory activity of SGI-1027 against DNMT3Acat J Biol Chem. 2015 Mar 6;290(10):6293-302.
DNMT3Acat 0.8 µM (IC50) To study the inhibitory activity of SGI-1027 against DNMT3Acat J Biol Chem. 2015 Mar 6;290(10):6293-302.
MDA-MB-468 triple-negative breast cancer cells 0-50 µM SGI-1027 reduces MYC protein level and expression of its target genes CDK4 and PD-L1 Bioorg Med Chem. 2021 Sep 1;45:116324.
HCT116 colon cancer cells 0-50 µM SGI-1027 inhibits MKK3-MYC protein-protein interaction, reduces MYC protein level and expression of its target genes CDK4 and PD-L1 Bioorg Med Chem. 2021 Sep 1;45:116324.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice NMDA-induced retinal injury model Intravitreal injection 10 µM Single injection, lasting 24 hours SGI-1027 induced Oct4 expression in MG at 24hpi after retinal injury. Front Neurosci. 2016 Nov 15;10:523
Mice Ovariectomy-induced osteoporosis model Intraperitoneal injection 2.5 mg/kg Once daily for 6 weeks SGI-1027 reversed promoter hypermethylation, GPX4 suppression and ferroptotic osteoporosis Bone Res. 2024 Dec 2;12(1):68.
Mice Calvarial osteolysis model Intraperitoneal injection 2.5 mg/kg Once daily for 2 weeks SGI-1027 significantly reversed TP-induced Gpx4 promoter hypermethylation and GPX4 repression, improving ferroptotic osteolysis to a similar extent as the ferroptosis inhibitor liproxstatin-1. Research (Wash D C). 2024 Aug 19;7:0457.
ICR mice D-galactose-induced accelerated aging model Intraperitoneal injection 2.5 mg/kg Daily for 8 weeks Evaluate the protective effect of SGI-1027 on D-gal-induced renal aging Aging Cell. 2022 Jan;21(1):e13526.
Nude mice A-498 cell subcutaneous xenograft model Oral gavage 30 mg/kg/day (SGI-1027) and 2 mg/kg/day (everolimus) Once daily for 16 days To evaluate the in vivo anti-tumor effect of SGI-1027 in combination with everolimus, the results showed that the combination treatment significantly inhibited tumor growth and induced GSDME-dependent pyroptosis Adv Sci (Weinh). 2024 Oct;11(38):e2404693.
BALB/c nude mice HeLa cell xenograft model Oral gavage 50 mg/kg/day Once daily for 30 consecutive days To evaluate the effect of SGI-1027 in combination with AH057 on tumor volume, results showed that the combined treatment significantly reduced tumor volume. Cell Death Dis. 2020 Sep 7;11(9):724.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.83mL

2.17mL

1.08mL

21.67mL

4.33mL

2.17mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Garcia-Dominguez P, Dell'aversana C, et al. Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1631-5.

[2]Datta J, Ghoshal K, et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 2009 May 15;69(10):4277-85.

[3]Holliday R, Pugh JE. DNA modification mechanisms and gene activity during development. Science. 1975 Jan 24;187(4173):226-32.

[4]Gros C, Fleury L, Nahoum V, Faux C, Valente S, Labella D, Cantagrel F, Rilova E, Bouhlel MA, David-Cordonnier MH, Dufau I, Ausseil F, Mai A, Mourey L, Lacroix L, Arimondo PB. New insights on the mechanism of quinoline-based DNA Methyltransferase inhibitors. J Biol Chem. 2015 Mar 6;290(10):6293-302.

[5]Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG, Phiasivongsa P, Redkar S, Jacob ST. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 2009 May 15;69(10):4277-85.

[6]Sun N, Zhang J, Zhang C, Zhao B, Jiao A. DNMTs inhibitor SGI-1027 induces apoptosis in Huh7 human hepatocellular carcinoma cells. Oncol Lett. 2018 Nov;16(5):5799-5806.

[7]Reyes-Aguirre LI, Lamas M. Oct4 Methylation-Mediated Silencing As an Epigenetic Barrier Preventing Müller Glia Dedifferentiation in a Murine Model of Retinal Injury. Front Neurosci. 2016 Nov 15;10:523.

 

Historical Records

Categories